This website is intended for UK healthcare professionals only Log in | Register

Tag Archives: depression

June 2017 Br J Cardiol 2017;24:61

In brief

BJCardio Staff

Abstract

Nanoparticles, inhaled from sources such as vehicle exhausts, have been shown to cross from the lungs into the blood stream. They can then accumulate in areas susceptible to heart problems, according to research part-funded by the British Heart Foundation.  Previous studies have identified a correlation but not a causal link between nanoparticles and strokes or cardiovascular disease. It is not currently possible to measure environmental nanoparticles in the blood. So, researchers from the University of Edinburgh, and the National Institute for Public Health and the Environment in the Netherlands, used a variety of specialist techniques to t

| Full text

December 2015 Br J Cardiol 2016;23:(1) Online First

Pulmonary hypertension news from AHA and ERS

BJCardio Staff

Abstract

News from ERS High levels of anxiety and depression in PH Psychological morbidity remains under-diagnosed in pulmonary hypertension (PH), and one third of patients suffer from depression and/or anxiety for which only 38% are being treated, according to a study conducted by Dr Gina Somaini and colleagues (University Hospital of Zurich, Switzerland). They investigated the prevalence and course of anxiety and depression and their association with health-related quality of life (HRQoL) disease markers and survival over a mean period of 16 months. In the study, 45 newly diagnosed and 86 pretreated patients with arterial and chronic thromboembolic

| Full text

August 2015 Br J Cardiol 2015;22:92–3

In brief

BJCardio Staff

Abstract

PCSK9 approvals in Europe Two agents in a new cholesterol-lowering class – the PCSK9 inhibitors, which use human monoclonal antibodies to target PCSK9 (proprotein convertase subtilisin/kexin type 9) – have received European approval for lowering cholesterol. Evolocumab (Repatha®, Amgen) is the first PCSK9 inhibitor to be granted marketing authorisation by the European Commission (EC) for use in people with primary hypercholesterolaemia or mixed dyslipidaemia, or in homozygous familial hypercholesterolaemia, who are unable to reach low-density lipoprotein cholesterol (LDL-C) goals with an optimal dose of statin (or a statin and other lipi

| Full text
Meeting the psychological needs of cardiac patients: an integrated stepped-care approach within a cardiac rehabilitation setting

July 2010 Br J Cardiol 2010;17:175-9

Meeting the psychological needs of cardiac patients: an integrated stepped-care approach within a cardiac rehabilitation setting

Alison Child, Jane Sanders, Paul Sigel, Myra S Hunter

Abstract

(more…)

| Full text

May 2006 Br J Cardiol 2006;13:220-4

Anxiety, depression and myocardial infarction: a survey of their impact on consultation rates before and after an acute primary episode

Everard W Thornton, Peter Bundred, Michelle Tytherleigh, Ann DM Davies

Abstract

No content available

| Full text

September 2005 Br J Cardiol 2005;12:361-6

Cardiac rehabilitation: results of a national survey

Allison Thorpe, Sian Griffiths, Charles F George

Abstract

No content available

| Full text
Close

You are not logged in

You need to be a member to print this page.
Find out more about our membership benefits

Register Now Already a member? Login now
Close

You are not logged in

You need to be a member to download PDF's.
Find out more about our membership benefits

Register Now Already a member? Login now